The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Bringing bispecifics into everyday practice in LBCL: overcoming toxicity challenges
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, briefly discusses the challenges of bringing bispecifics into community practice for patients with large B-cell lymphoma (LBCL), largely due to therapy-related toxicities. Dr Alderuccio explains that these toxicities can often be managed with dexamethasone and highlights debulking strategies, which can help mitigate these toxicities. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
